Home > Dermatology > EADV 2022 > Early emollient use may reduce AD risk in infants

Early emollient use may reduce AD risk in infants

Presented By
Prof. Alan Irvine, Trinity College Dublin, Ireland
Conference
EADV 2022
Trial
STOP AD
Infants with a high risk to develop atopic dermatitis (AD) that started an 8-week intervention with emollients directly after birth had a significant risk reduction for AD, showed the STOP AD study. Babies treated twice daily with the emollient maintained AD-free skin for a significantly longer period in the first 12 months than the control group. Irish researchers set up the single centre, investigator-blinded STOP AD study (NCT03871998) that tested short-term emollient use for its capacity to prevent AD [1]. The 321, randomised, high-risk infants with a family history of AD were included from birth to ≤4 days. The intervention arm of the study immediately started an 8-week course with a ceramide dominant emollient at a dose of about 7 fingertip units applied twice daily. The control arm infants received standard...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on